The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

• Giuseppe Bronte,
• Giuseppe Bronte,
• Alessia Belloni,
• Luana Calabrò,
• Luana Calabrò,
• Lucio Crinò

Affiliations

Giuseppe Bronte

Clinic of Laboratory and Precision Medicine, National Institute of Health and Sciences on Ageing (IRCCS INRCA), Ancona, Italy

Giuseppe Bronte

Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy

Alessia Belloni

Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle Marche, Ancona, Italy

Luana Calabrò

Department of Oncology, University Hospital of Ferrara, Cona, Italy

Luana Calabrò

Department of Translational Medicine, University of Ferrara, Ferrara, Italy

Lucio Crinò

Department of Medical Oncology, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) “Dino Amadori”, Meldola, Italy